home / stock / dnli / dnli news


DNLI News and Press, Denali Therapeutics Inc. From 12/03/23

Stock Information

Company Name: Denali Therapeutics Inc.
Stock Symbol: DNLI
Market: NASDAQ
Website: denalitherapeutics.com

Menu

DNLI DNLI Quote DNLI Short DNLI News DNLI Articles DNLI Message Board
Get DNLI Alerts

News, Short Squeeze, Breakout and More Instantly...

DNLI - Denali Therapeutics Inc. $DNLI Investment Analysis and Advice

2023-12-03 00:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

DNLI - Biogen: LAQEMBI's $10 Billion Potential

2023-11-29 15:00:01 ET Summary Biogen's latest Alzheimer's drug, Aduhelm, faced challenges after FDA approval, leading to concerns about efficacy and high costs. Biogen and Eisai's latest FDA-approved lecanemab faces similar risks; as a result, shares are down over 20% year-over-y...

DNLI - JP Morgan bullish on six Big Biotechs, rates nine others neutral or lower

2023-11-25 16:32:53 ET More on BioCryst Pharmaceuticals, Crinetics Pharmaceuticals, etc. Mirum Pharmaceuticals, Inc. (MIRM) Q3 2023 Earnings Call Transcript BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2023 Earnings Call Transcript Immunocore: First Half Of 2024 IMC-F106...

DNLI - Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics

Flagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics PR Newswire Quotient's Somatic Genomics platform reveals new approaches to treat disease based on the vast genetic variation present in the body's trilli...

DNLI - Tracking Baillie Gifford's 13F Portfolio - Q3 2023 Update

2023-11-15 01:56:28 ET Summary Baillie Gifford's 13F portfolio value decreased from ~$118B to ~$110B this quarter. The top three holdings in the portfolio are MercadoLibre, NVIDIA, and Tesla. There were stake increases in companies such as PDD Holdings, Coupang, and BeiGene, a...

DNLI - Denali Therapeutics GAAP EPS of -$0.72 beats by $0.09, revenue of $1.27M misses by $9.89M

2023-11-07 17:20:20 ET More on Denali Therapeutics Denali's New Summit: Changing Hunter Syndrome Landscape Seeking Alpha’s Quant Rating on Denali Therapeutics Historical earnings data for Denali Therapeutics Financial information for Denali Therapeutic...

DNLI - Denali Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights

SOUTH SAN FRANCISCO, Calif., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (BBB) for the treatment of neurodegenerative diseases and lysosomal st...

DNLI - Expected US Company Earnings on Thursday, November 2nd, 2023

Acushnet Holdings Corp. (GOLF) is expected to report $0.54 for Q3 2023 Paramount Global (PARA) is expected to report $0.09 for Q3 2023 Curis Inc. (CRIS) is expected to report $-2.32 for Q3 2023 Quanta Services Inc. (PWR) is expected to report $1.99 for Q3 2023 GRI Bio Inc. (GRI) i...

DNLI - Expected earnings - Denali Therapeutics Inc.

Denali Therapeutics Inc. (DNLI) is expected to report $-0.83 for Q3 2023

DNLI - Flagship Pioneering Launches Pioneering Intelligence

Flagship Pioneering Launches Pioneering Intelligence PR Newswire CAMBRIDGE, Mass. , Nov. 1, 2023 /PRNewswire/ -- Flagship Pioneering today launched Pioneering Intelligence, an initiative of Flagship Pioneering harnessing artificial intelligence (AI) to accelerate...

Previous 10 Next 10